חוב לטווח ארוך: lisata.com (LSTA)

Lisata Therapeutics (LSTA) is developing targeted drug delivery systems for malignant tissues, strengthening its authority among physicians. This linear price chart below demonstrates metrics where long-term debt stands at 0.00. David Mazzo's team is focused on completing Phase II trials for pancreatic therapy, although global technological protectionism and restrictions on cross-border data exchange are hindering the scaling of their software.

For Lisata Therapeutics (LSTA), with its focus on the CendR platform and M&A potential, long-term liabilities define the balance between financial stability and the resources required to scale clinical trials. The current value of 0.00 reflects the aggregate of loans with maturities exceeding one year, which allows for an assessment of the risk of dependence on Fed rates and the issuer's investment capacity through the time series of the business's long-term debt capital.